Linda S Scarborough, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 221 W Maple Ave, Fayetteville, WV 25840 Phone: 304-574-3960 Fax: 304-574-2179 |
Faith A Tyler, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: Rr 3 Box 9, 439 Elizabeth Way, Fayetteville, WV 25840 Phone: 304-574-2600 Fax: 304-574-2951 |
Christina L. Phares, FNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 127 Oakwood Cir, Fayetteville, WV 25840 Phone: 304-763-8223 |
Mrs. Rose Anne Michaels, MSN, FNP-BC Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 111 Windsor Ln, Fayetteville, WV 25840 Phone: 304-444-3539 |
Heidi E Dolin, FNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 439 Elizabeth Hwy, Fayetteville, WV 25840 Phone: 304-574-2600 Fax: 304-574-2951 |
News Archive
Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.
There's more than one type of fat cell. Besides the white fat that stores triglycerides in lipid droplets in preparation for lean times later, mammals also have heat-generating brown fat, which acts more like a radiator than a storage closet.
Seeking ways to change cancer patients' perceptions and negative attitudes towards clinical trials participation, researchers at Moffitt Cancer Center conducted a study offering two different kinds of intervention to two groups of adults with cancer who had not previously been asked to participate in clinical trials. They found a multimedia psychoeducational intervention to be more effective in changing patients' perceptions and negative attitudes toward clinical trials than standard educational literature.
ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.
A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.
› Verified 5 days ago